Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 440.92 Million SEK | 29.37% |
| 2022 | 292.5 Million SEK | 41.29% |
| 2021 | 207.02 Million SEK | 23.75% |
| 2020 | 167.28 Million SEK | 5.32% |
| 2019 | 158.84 Million SEK | 29.7% |
| 2018 | 122.47 Million SEK | 15.43% |
| 2017 | 106.09 Million SEK | 7.27% |
| 2016 | 98.9 Million SEK | 28.73% |
| 2015 | 76.82 Million SEK | 34.87% |
| 2014 | 56.96 Million SEK | 29.85% |
| 2013 | 43.86 Million SEK | 290.88% |
| 2012 | 11.22 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 116.11 Million SEK | 2.63% |
| 2024 Q2 | 124.81 Million SEK | 7.5% |
| 2024 Q3 | 127.45 Million SEK | 2.12% |
| 2023 Q4 | 113.14 Million SEK | 10.6% |
| 2023 Q3 | 102.29 Million SEK | -8.39% |
| 2023 Q1 | 93.61 Million SEK | -0.95% |
| 2023 Q2 | 111.66 Million SEK | 19.28% |
| 2023 FY | 378.4 Million SEK | 29.37% |
| 2022 Q1 | 60.59 Million SEK | -15.44% |
| 2022 FY | 292.5 Million SEK | 41.29% |
| 2022 Q4 | 94.5 Million SEK | 27.66% |
| 2022 Q3 | 74.02 Million SEK | 16.82% |
| 2022 Q2 | 63.36 Million SEK | 4.57% |
| 2021 Q2 | 53.89 Million SEK | 36.46% |
| 2021 Q4 | 71.66 Million SEK | 70.76% |
| 2021 Q3 | 41.96 Million SEK | -22.14% |
| 2021 FY | 207.02 Million SEK | 23.75% |
| 2021 Q1 | 39.49 Million SEK | -10.89% |
| 2020 FY | 167.28 Million SEK | 5.32% |
| 2020 Q2 | 31.31 Million SEK | -11.44% |
| 2020 Q3 | 51.79 Million SEK | 65.41% |
| 2020 Q4 | 44.32 Million SEK | -14.43% |
| 2020 Q1 | 35.35 Million SEK | -19.78% |
| 2019 Q1 | 38.77 Million SEK | 7.18% |
| 2019 FY | 158.84 Million SEK | 29.7% |
| 2019 Q3 | 36.26 Million SEK | -8.69% |
| 2019 Q4 | 44.07 Million SEK | 21.54% |
| 2019 Q2 | 39.71 Million SEK | 2.43% |
| 2018 Q1 | 26.96 Million SEK | 0.22% |
| 2018 FY | 122.47 Million SEK | 15.43% |
| 2018 Q4 | 36.18 Million SEK | 19.41% |
| 2018 Q3 | 30.3 Million SEK | 4.37% |
| 2018 Q2 | 29.03 Million SEK | 7.67% |
| 2017 Q2 | 27.24 Million SEK | 0.63% |
| 2017 Q1 | 27.07 Million SEK | -4.21% |
| 2017 FY | 106.09 Million SEK | 7.27% |
| 2017 Q4 | 26.9 Million SEK | 8.18% |
| 2017 Q3 | 24.87 Million SEK | -8.72% |
| 2016 Q2 | 23.19 Million SEK | 3.2% |
| 2016 Q1 | 22.47 Million SEK | 16.39% |
| 2016 FY | 98.9 Million SEK | 28.73% |
| 2016 Q4 | 28.26 Million SEK | 13.2% |
| 2016 Q3 | 24.96 Million SEK | 7.64% |
| 2015 Q2 | 20.23 Million SEK | 3.59% |
| 2015 Q1 | 19.53 Million SEK | 3.25% |
| 2015 FY | 76.82 Million SEK | 34.87% |
| 2015 Q4 | 19.31 Million SEK | 8.76% |
| 2015 Q3 | 17.75 Million SEK | -12.24% |
| 2014 FY | 56.96 Million SEK | 29.85% |
| 2014 Q4 | 18.91 Million SEK | 38.17% |
| 2014 Q2 | 13.22 Million SEK | 18.72% |
| 2014 Q1 | 11.13 Million SEK | -15.12% |
| 2014 Q3 | 13.69 Million SEK | 3.53% |
| 2013 Q4 | 13.12 Million SEK | 22.83% |
| 2013 Q2 | 10.44 Million SEK | 8.63% |
| 2013 FY | 43.86 Million SEK | 290.88% |
| 2013 Q1 | 9.61 Million SEK | -14.31% |
| 2013 Q3 | 10.68 Million SEK | 2.26% |
| 2012 Q4 | 11.22 Million SEK | 0.0% |
| 2012 FY | 11.22 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -432.196% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 27.93% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 27.93% |
| Arcoma AB | 53.25 Million SEK | -727.995% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -8773.496% |
| BICO Group AB (publ) | 2.84 Billion SEK | 84.52% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | -109.521% |
| CellaVision AB (publ) | 295.99 Million SEK | -48.966% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -539.669% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -33579.325% |
| C-Rad AB (publ) | 3.8 Million SEK | -11503.263% |
| Duearity AB (publ) | 21.58 Million SEK | -1942.733% |
| Dignitana AB (publ) | 74.73 Million SEK | -489.975% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -16230.519% |
| Getinge AB (publ) | 10.75 Billion SEK | 95.902% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -2318.864% |
| Iconovo AB (publ) | 63.35 Million SEK | -595.964% |
| Integrum AB (publ) | 90.57 Million SEK | -386.824% |
| Luxbright AB (publ) | 23.09 Million SEK | -1809.546% |
| Mentice AB (publ) | 237.06 Million SEK | -85.997% |
| OssDsign AB (publ) | 175.6 Million SEK | -151.094% |
| Paxman AB (publ) | 133.8 Million SEK | -229.54% |
| Promimic AB (publ) | 48.55 Million SEK | -808.148% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -171.53% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -530.107% |
| ScandiDos AB (publ) | 61.03 Million SEK | -622.376% |
| Sectra AB (publ) | 39.06 Million SEK | -1028.751% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -152.638% |
| Senzime AB (publ) | 141.51 Million SEK | -211.57% |
| SpectraCure AB (publ) | 12.12 Million SEK | -3535.587% |
| Stille AB | 87.21 Million SEK | -405.537% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 92.08% |